Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 12Triple Negative Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Fallopian Tube Neoplasms 4Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Vaccinia 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Pathologic Complete Response 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1HER2-negative Breast Cancer 1Gastric Adenocarcinoma 1Carcinoma, Small Cell 1Breast Diseases 1Brain Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Cisplatin 7Etoposide 5pembrolizumab 4Topotecan 4Pemetrexed 4Gemcitabine 3Carboplatin 3belinostat 2Temozolomide 2RRx-001 2Paclitaxel 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1bemiparin 1belotecan 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Small Cell × taxane × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡